Clinical Trial Update: TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating bortezomib to overcome epigenetic therapy resistance in acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: University Hospital Heidelberg | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED